Cargando…
Commentary: Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer
Autores principales: | Ripoll, Giselle V., Pifano, Marina, Garona, Juan, Alonso, Daniel F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6970191/ https://www.ncbi.nlm.nih.gov/pubmed/31998646 http://dx.doi.org/10.3389/fonc.2019.01490 |
Ejemplares similares
-
Peptide Agonists of Vasopressin V2 Receptor Reduce Expression of Neuroendocrine Markers and Tumor Growth in Human Lung and Prostate Tumor Cells
por: Pifano, Marina, et al.
Publicado: (2017) -
Preclinical Efficacy of [V(4)Q(5)]dDAVP, a Second Generation Vasopressin Analog, on Metastatic Spread and Tumor-Associated Angiogenesis in Colorectal Cancer
por: Garona, Juan, et al.
Publicado: (2019) -
The novel desmopressin analogue [V(4)Q(5)]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models
por: GARONA, JUAN, et al.
Publicado: (2015) -
Reduction of tumor angiogenesis induced by desmopressin in a breast cancer model
por: Ripoll, Giselle V., et al.
Publicado: (2013) -
A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients
por: Weinberg, Ruth S, et al.
Publicado: (2015)